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Abstract: Venous thromboembolic disorders (VTE) are serious disorders with high morbidity and 
mortality rates. Many genetic and acquired risk factors were identified to cause VTE
common genetic risk factor is Factor V Leiden mutation (
of populations of Caucasian origin but was almost absent in non
populations living in North Africa and the Middle East.  This review article briefly explains FVL 
and  how  it  causes  VTE,  the  distribution  of  FVL  worldwide,  and  then  it  elaborates  on  the 
epidemiology of FVL in the Mediterranean Region and how this brought speculations that FVL 
might have originated in the Eastern Mediterranean area. 
Introduction: Thrombophilia  is  the  term  given  to 
abnormal  blood  coagulation  condition  leading  to 
increased  tendency  towards  coagulation 
(hypercoagulability  status).  People  with 
hypercoagulability  are  at  risk  of  developing 
thrombosis,  especially  venous  thromboembolic 
disorders  (VTE)  including  deep  vein  thrombosis 
(DVT)  and  pulmonary  embolism  (PE).  VTE  is  a 
significant cause of morbidity and mortality in many 
countries with an annual incidence of 1/1000.
genetic and acquired risk factors for the development 
of VTE were identified. In fact, the WHO expert group 
(1996) defined thrombophilia as a tendency to develop 
VTE that may be genetically determined, acquired or 
both.
5 Genetic  factors  include  activated  protein  C 
resistance  (APC-R)  associated  with  Factor  V  Leiden 
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Venous thromboembolic disorders (VTE) are serious disorders with high morbidity and 
mortality rates. Many genetic and acquired risk factors were identified to cause VTE
common genetic risk factor is Factor V Leiden mutation (FVL). FVL was found in high percentage 
of populations of Caucasian origin but was almost absent in non-Caucasians. It was also reported in 
populations living in North Africa and the Middle East.  This review article briefly explains FVL 
TE,  the  distribution  of  FVL  worldwide,  and  then  it  elaborates  on  the 
epidemiology of FVL in the Mediterranean Region and how this brought speculations that FVL 
might have originated in the Eastern Mediterranean area. 
Thrombophilia  is  the  term  given  to 
abnormal  blood  coagulation  condition  leading  to 
increased  tendency  towards  coagulation 
(hypercoagulability  status).  People  with 
risk  of  developing 
thrombosis,  especially  venous  thromboembolic 
disorders  (VTE)  including  deep  vein  thrombosis 
(DVT)  and  pulmonary  embolism  (PE).  VTE  is  a 
significant cause of morbidity and mortality in many 
countries with an annual incidence of 1/1000.
1-4 Many 
genetic and acquired risk factors for the development 
WHO expert group 
(1996) defined thrombophilia as a tendency to develop 
VTE that may be genetically determined, acquired or 
Genetic  factors  include  activated  protein  C 
R)  associated  with  Factor  V  Leiden 
mutation  (FVL),  Prothrombin  G20210A  mutation 
associated  with  high  levels  of  prothrombin,  genetic 
deficiencies  of  proteins  C,  S  and  antithrombin,  and 
others.  Acquired  risk  factors  include  lupus 
anticoagulants, pregnancy, use of contraceptives, major 
surgeries,  cancer,  inflammations,  and  others.  This 
review  article  focuses  on the  epidemiology  of  APC
R/FVL  in  the  Mediterranean  area.  For  a  better 
understanding  of  the  pathophysiology  involved  in 
causing hypercoagulability by APC
helpful to start by a quick revision of the process of 
coagulation and its associated natural anticoagulants.    
Blood  Coagulation: Normally,  blood  loss  through 
injured vessels is prevented by a normal physiological 
process  called  “Hemostasis”.  Normal  human
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Venous thromboembolic disorders (VTE) are serious disorders with high morbidity and 
mortality rates. Many genetic and acquired risk factors were identified to cause VTE. The most 
FVL). FVL was found in high percentage 
Caucasians. It was also reported in 
populations living in North Africa and the Middle East.  This review article briefly explains FVL 
TE,  the  distribution  of  FVL  worldwide,  and  then  it  elaborates  on  the 
epidemiology of FVL in the Mediterranean Region and how this brought speculations that FVL 
mutation  (FVL),  Prothrombin  G20210A  mutation 
associated  with  high  levels  of  prothrombin,  genetic 
deficiencies  of  proteins  C,  S  and  antithrombin,  and 
ired  risk  factors  include  lupus 
anticoagulants, pregnancy, use of contraceptives, major 
surgeries,  cancer,  inflammations,  and  others.  This 
review  article  focuses  on the  epidemiology  of  APC-
R/FVL  in  the  Mediterranean  area.  For  a  better 
pathophysiology  involved  in 
causing hypercoagulability by APC-R/FVL, it may be 
helpful to start by a quick revision of the process of 
coagulation and its associated natural anticoagulants.    
Normally,  blood  loss  through 
injured vessels is prevented by a normal physiological 
process  called  “Hemostasis”.  Normal  humanMediterr J Hematol Infect Dis 2011; 3: Open Journal System
Figure 1. The processes of coagulation and fibrinolysis as a series of chemical reactions leading to the formation of a clot to stop bleeding 
from the site of injury, and then removing the clot afterwards. Solid lines indicate activation process, while dashed lines indicate inactivation 
process.  Abbreviations:  antithrombin  (AT),  protein  C  (PC),  activated  protein  C  (APC),  protein  S  (PS),  phospholipids  (PL),  lupus 
anticoagulants (LA), tissue plasminogen activator (tPA), tPA inhibitor (tPAI), α2 antiplasmin (α2AP), thrombin activatable fibrinolysis 
inhibitor (TAFI). 
hemostasis is a balanced system which, on one hand, 
prevents  excessive  bleeding  from  any  injured  site, 
while  on  the  other  hand  maintains  blood  circulation 
inside intact blood vessels by inhibiting intravascular 
coagulation. An efficient hemostatic process possesses 
intrinsic well-balanced regulatory systems, involving a 
number  of  dynamic  mechanisms  and  chemical  and 
physical reactions. It usually includes platelets, blood 
vessels  and  the  coagulation  system.  In  blood 
coagulation,  a  prominent  response  to  an  injury  is 
recruited in  the  form of  series  of stepwise (cascade) 
chemical interactions leading to fibrin formation. This 
complex  system  involves  certain  proteins  called  the 
plasma  clotting  factors  (enzymes).  These  enzymes 
circulate  in  the  blood  in  an  inactive  form,  and  get 
activated in case of vessel injury. In summary, when a 
blood  vessel  is  injured,  the  coagulation  cascade  is 
initiated by the release of tissue factor (thromboplastin) 
and  the  exposure  of  intravascular  collagen,  which 
activates  clotting  factors  VII  and  XII,  respectively. 
These clotting factors activate other clotting factors in 
a stepwise procedure ending up with the formation of a 
fibrin clot. A fibrin clot, in association with platelets, 
form  a  plug  that  blocks  the  injured  blood  vessel, 
preventing bleeding and allowing for wound healing. 
After healing, the fibrin clot is dissolved by the enzyme 
plasmin  in  a  process  called  fibrinolysis.  The  whole 
process  is  under  careful supervision  by  three  main 
proteins that circulate normally in the blood; namely 
protein  C  (and  its  active  form  activated  protein  C; 
APC), protein S (PS) and antithrombin (AT). These so-
called “natural anticoagulants”  monitor the  processes 
of  coagulation  and  fibrinolysis  in  order  to  prevent 
excessive clotting.
6,7,8 Abnormalities in clotting factors 
may  lead  to  bleeding  problems  (hemophilia),  while 
abnormalities in the natural anticoagulants may lead to Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
Figure 2. FV molecule showing arginine 506 as a main point of action for APC which is negatively affected by FVL.
hypercoagulability  and  thrombosis,  with  certain 
exceptions  in  both.  Figure  1 gives  an  illustrative 
drawing  of  the  process  of  coagulation  and  its 
associated  fibrinolysis  process  and  natural 
anticoagulants.
Activated  Protein  C  Resistance  and  Factor  V 
Leiden Mutation: In 1993, a Swedish research team 
led  by  B.  Dahlbäck  recognized  an  unusual 
phenomenon  affecting  the  coagulation  system.  They 
were studying the effect of addition of external APC to 
plasma of patients with VTE. Normally, APC should 
inactivate  clotting  Factor  V  (FV)  (Figure  1)  and 
therefore slow down the coagulation process. However, 
in certain patients studied by Dahlbäck and his team, 
this  slowing  down  did  not  occur.  They  called  this 
phenomenon  “APC  resistance”,  and  they  originally 
though this could be due a deficiency in a yet unknown 
protein  that  co-helps  APC  in  inactivating  FV.
9 One 
year later, another group of researchers from Holland, 
led  by  R.  M.  Bertina,  discovered  a  missense  point 
mutation in the FV gene, where adenine (A) replaced 
guanine (G) at nucleotide position 1691 of exon 10 of 
the FV gene, only eleven nucleotides upstream of the 
beginning of intron 10. They called this mutation as FV 
Leiden mutation (FVL) after the Dutch city where they 
made their discovery in.
10 This nucleotide replacement 
happened to be in the codon for the amino acid residue 
arginine 506 (CGA) normally present in the factor V 
molecule,  creating  a  new  codon  (CAA)  which  is 
translated as glutamine. In order to inactivate FV, APC 
needs to recognize arginine at position 506 of the FV 
molecule (Figure 2). Because of the amino acid change 
in FVL, APC can no longer inactivate FV efficiently, 
but FV retains its coagulation capabilities and therefore 
carriers of FVL develop hypercoagulability which may 
clinically  manifest  as  VTE  episodes.  Later  studies 
showed that people with FVL were at higher risk of 
developing VTE (10-fold in heterozygous carriers and 
30 to 140-fold in homozygous carriers).
9-16 In addition, 
most  homozygotes  for  FVL  were  reported to  get  at 
least one VTE event in their life time.
17,18 This explains 
the  great  clinical  and  scientific  consideration  this 
mutation  had  appealed  and  the  hundreds  of  studies 
conducted  on  its  prevalence  and  risk  for  developing 
VTE in almost every part of the world. 
World  Distribution  of  Factor  V  Leiden:  Since  its 
discovery, several studies were conducted to determine 
the prevalence of FVL mutation in normal subjects and 
in patients with VTE, as well as to measure the risk 
value of this mutation in developing VTE. First reports
appeared in Europe, which concentrated on populations 
of Caucasian origin. They found FVL to be present in a 
quite high percentage of patients with VTE (15-65%) 
and  healthy  subjects  (1-15%).  Similar  results  were 
obtained  when  Caucasians  where  studied  in  non-
European  countries  like  USA,  Australia  and  Israel. 
Table 1 gives examples of studies on FVL in European 
and non-European Caucasians.
2,3,10,12,14-16,19-64 However, 
when studies where extended to other ethnic groups, 
FVL  was  surprisingly  found  to  be  very  rare  in 
Africans,  South-East  Asians,  Chinese,  Japanese, 
American Indians, Greenland Eskimos and Aboriginals 
of  Australia  (Table  2).
21,58,61,65-78 These  findings 
suggested that FVL might  have occurred as a single 
event  sometime  in  the  distant  past  in  a  common 
European Caucasian ancestor, whose offspring are the 
present time Caucasian carriers of this mutation living 
in  Europe  and  other  countries.  This  assumption  was 
later  strengthened  by  molecular  studies  that  reported 
FVL  to  be  always  associated  with  one  haplotype  of 
single nucleotides polymorphisms (SNPs), as will be 
discussed  later.  Later  on, studies  were  conducted  onMediterr J Hematol Infect Dis 2011; 3: Open Journal System
Table 1. Prevalence of FVL in Caucasian patients with VTE and normal subjects living in European and non-European countries. European 
countries on the Mediterranean Sea are shown.
Country
VTE
patients (%)
Normal
Population (%)
Reference
E
u
r
o
p
e
a
n
C
a
u
c
a
s
i
a
n
s
N
o
n
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e
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UK ---- 1.74-5.6 19, 20
Sweden 41.5-50 7.5-11.4 14, 15, 19
Poland ---- 5 21
Netherlands 21 2 10, 20
Germany 30 7.1-12 22, 23
Belgium 22 3.3 24
Slovakia 29.5-37.0 4 25, 26
Austria 26 ---- 27
Hungary 44 6.9 28, 29
Serbia 29.9 5.8 30
Azerbaijan ---- 14 31
E
u
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e
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C
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s
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e
d
i
t
e
r
r
a
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e
a
n
Spain 9.2-26.3 1.6-5.8 32-37
France 9-18 3.5-5.0 38-41
French/ Spanish
         Basques ---- 0-0.7 42, 43
Italy 9.0-42.8 2-13.1 12, 44-47
Yugoslavia 15.5 4.0 48
Slovenia 12.9 6.3 49
Croatia 21.0-28.2 2.4-4.0 50-52
Albania/Kosovo ---- 3.4 53
Greece 16.2-31.9 2.5-7.0 2, 54-57
N
o
n
E
u
r
o
p
e
a
n
C
a
u
c
a
s
i
a
n
s USA 8.6 3.2-6.0 3, 16, 58
Australia ---- 4-10.2 59-62
Israel ---- 4.3 63
Brazil 20 2 64
Arabs and populations living in the Middle East and 
North Africa (The MENA region), as summarized in 
Table  3.
31,63,79-133 These  studies  showed  a  high 
prevalence of FVL in these populations, who are not 
usually classified as Caucasians. However, the MENA 
region is geographically very close to Europe and had 
witnessed  a  lot  of  human  movement  from  and  to 
Europe,  and hence  such  populations  are  expected  to 
have some Caucasian genes in their DNA. Therefore, 
the  presence  of  FVL  in  Arabs  and  North  African 
populations should not be a surprising upshot. 
Factor  V  Leiden  in  the  Mediterranean  Region: 
Currently, there are 20 countries that have seacoasts on 
the  Mediterranean  Sea  and  therefore  are  called  the 
Mediterranean countries; 5  are in  North Africa, 4 in 
West Asia and 11 in South Europe. Figure 3 gives a 
map  of  the  Mediterranean  Sea  and  its  countries, 
showing  the  prevalence  of  FVL  in  these  countries 
which are based on the studies listed in tables 1 and 3. 
No  data  could  be  retrieved  from  the  literature  on 
prevalence  of  FVL  in  Libya,  Malta,  Bosnia  or 
Montenegro.  However,  one  study  reported  FVL  in 
Yugoslav people which included patients and healthy 
subjects  from  all  over  the  former  Yugoslavia,  and 
possibly some of their subjects were from Bosnia and 
Montenegro.
48 There  were  no  reports  from  Albania 
itself,  but  one  study  was  conducted  in  Kosovo,  the 
people of which are considered as Albanians.
53 In table 
1, the prevalence of FVL in the people of the Basques 
was  put  separately,  although  not  being  a  separate 
country, because of the unique rarity of FVL in these 
people.
42,43 This has an important issue which will be 
discussed later. In Israel, the population consists of a 
mixture  of  Palestinian  Arabs  and  other  immigrants 
from  different  parts  of  the  world,  largely  being  of 
European Caucasian origin. Therefore, the results there 
were  split  between  tables  1  and  3 according  to  the 
origin of the studied populations.   
One  may  notice  that  the  prevalence  of  FVL  is 
present in its maximum peak in this part of the World. 
In addition, there is generally an Eas-to-West decline in 
prevalence of FVL in these countries. This observation 
was  also  noticed  by  Lucotte  et  al  (2001)  who  also 
observed a South-to-North decline of these values in 
Europe,  only  when  southwestern  populations  were 
excluded.
134 These  observations  raised  discussions  in 
the literature on the exact place where FVL has first 
appeared. 
Has  Factor  V  Leiden  originated  in  the  Eastern 
Mediterranean? As was mentioned before, the first Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
Table 2. Prevalence of FVL in non-Caucasian patients with VTE and normal subjects in different parts of the world.
Country/
Ethnic groups
VTE
patients (%)
Normal
Population (%)
Reference
Asians Japan 0 0 65-68
Korea 0 ---- 69
China 0 0 70, 71
Indonesia ---- 0 70
Malaysia 0.5 ---- 72
Singapore 5 ---- 72
India 3 1.3 21, 73
Pakistan 1.25 ---- 74
USA ---- 0 75
Africans/ Ethiopia ---- 0 70,76
Black USA 1.4 0.9 58, 75
Sub-Sahara  ---- 0 70
Ecuador ---- 0 70
Venezuela ---- 4.4 77
Amerindians Ecuador ---- 0 70
Venezuela ---- 1.25 77
USA ---- 0 75
Eskimos Greenland  ---- 0 78
Indigenous
Australians Australia ---- 0 61
reports  on  the  prevalence  of  FVL  found  high 
prevalence of FVL in European Caucasians, while the 
prevalence was almost zero in other ethnic groups. In 
addition, studies showed an association of FVL with 
one haplotype in all carriers of the mutation. Therefore, 
scientists got a perception that FVL has occurred once 
in  the  past  time  in  one  European  Caucasian  person. 
Anthropology  proposes  that  Caucasoid  populations 
who settled in Europe were diverted from Mongoloid 
populations  (who  moved  to  East  Asia)  around  32
thousands  of  years  ago;  therefore  FVL  should  have 
appeared  sometime  earlier  than  32,000  years 
ago.
2,4,11,135-137 It  was  suggested  that  the mutation 
occurred in Europe first, and then spread to other parts 
of  the  world.  However,  the  observed  highest 
prevalence of FVL in Eastern Mediterranean countries 
have raised speculations that FVL might have occurred 
somewhere  there  and  then  spread  to 
Europe.
43,99,100,134,138,139 The  author  of  this  paper  has 
found FVL to be associated with one haplotype in 67 
Arabs from Eastern Mediterranean region, which was 
the same haplotype found in European carriers of the 
mutation,  giving  another  confirmation  that  FVL 
occurred  as  a  single  event  in  the 
Figure 3. Map of the Mediterranean Sea and its countries showing the prevalence of FVL in healthy populations living there.Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
Table 3. Prevalence of FVL in patients with VTE and normal subjects in Arabs and non-Arabs living in different Middle-Eastern and North 
African countries. Countries on the Mediterranean Sea are shown.
Country/
Ethnic groups
VTE
patients (%)
Normal
Population (%)
Reference
North Africa
Mediterranean
Morocco ---- 0 79-80
Algeria 13.8 1.3-2.0 81, 82
Tunisia 20.3-24.6 3.0-13.6 83-92
Egypt 30 2.5-10.2 93-97
Middle East
Mediterranean
Palestine
(inside & outside Israel)
---- 11.7-27.2 63, 97, 98
Lebanon 9.9-70.6 13.6-18.7 89, 92, 99-106 
Syria ---- 13.6 97, 99
Turkey 21-30.8 4.6-9.8 31, 107,108-115
Cyprus ---- 13.4 116
Middle East
Non-Mediterranean
Jordan 23.9-25.7 10.5-27.2 97, 117-122 
Iraq ---- 7.0 123
Kuwait 15.8 2-4.5 97, 124
Saudi Arabia ---- 0-2.5 89, 123, 125
Bahrain 52 3.1-14.7 89, 126
Oman 0 0 127
Yemen ---- 0 63
Iran 11.4 2.0-10.6 123, 128-133
past even in Arabs.
140 Castoldi et al (1997) suggested 
that FVL  probably  occurred  outside  Europe.
138 The 
rarity  of  FVL  in  the  French  and  Spanish  Basque 
populations, which are thought to be the oldest ethnic 
groups  in  Europe  of  Paleolithic  origin,  has  also 
suggested  FVL  to  occur  outside  Europe  first.
42,43
Lucotte et al (2001) proposed that FVL expanded in 
Europe during the  Neolithic  period, from a  probable 
Anatolian  center  of  origin  in  Turkey,  which  has 
occurred around 10,000 years ago.
134 This may explain 
the highest prevalence of FVL in East Mediterranean 
countries,  and  that  the  prevalence  decreases  when 
radiating  away  from  this  region  towards  Europe  or 
other  parts  of  the  world.  Still,  more  genetic  and 
molecular  studies  may  be  needed  to  detect  certain 
genetic loci or markers that may help in following the 
movement  of  carriers  of  FVL  in  the  Mediterranean 
region to definitely determine the exact location where 
FVL might have occurred first. 
Conclusions:  Molecular  and  epidemiological  studies 
provide evidences that FVL should have occurred as a 
single event in the past. The Mediterranean region has 
the  highest  prevalence  of  FVL  in  the  world.  This 
suggests it as the area where this mutation has arisen, 
possibly 10,000 years ago, and then it was spread to 
other parts of the world. 
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